Verve’s One-Time Gene Editor Cuts LDL by Nearly 70% in Early Trial
www.managedhealthcareexecutive.com
A phase 1b showed promising results in lowering LDL in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease.